Enanta Pharmaceuticals

Biotechnology ResearchMassachusetts, United States51-200 Employees

Enanta Pharmaceuticals is a biotechnology research company headquartered at 4 Kingsbury Avenue in Watertown, Massachusetts. The firm employs between 51 and 200 people and pursues small molecule drug discovery with a chemistry-centric approach, focusing on virology and immunology. Its clinical programs are centered on respiratory syncytial virus (RSV), while its early-stage immunology pipeline targets inflammatory diseases by inhibiting key drivers of the type 2 immune response, including KIT, STAT6, and MRGPRX2. Glecaprevir, a protease inhibitor discovered by Enanta, is used in hepatitis C treatment regimens and marketed by AbbVie as MAVYRET in the United States and MAVIRET elsewhere, with royalties from these products providing ongoing funding to Enanta. The company has ongoing research and development activities including the KIT inhibitor EDP-978 in Phase 1 for urticaria, and zelicapavir, an oral RSV N-protein inhibitor evaluated in Phase IIb, along with a launched STAT6 inhibitor program.

Sign up for free to view info

Email Format Employee directory